Compound Tirzepatide Dosage Chart: Every Concentration, Every Dose, Every Unit Conversion

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide dosing follows the same milligram escalation schedule as brand-name Mounjaro (2.5 mg to 15 mg), but unit conversions depend entirely on your vial's concentration
• At 10 mg/mL (most common), the starting dose of 2.5 mg equals 25 units on a U-100 syringe; at 5 mg/mL it's 50 units, at 20 mg/mL it's 12.5 units
• The standard titration schedule increases by 2.5 mg every four weeks, but clinical practice data shows 23% of patients require extended time at lower doses to manage gastrointestinal adaptation
• Dose conversions between concentrations are not interchangeable without recalculation, the most common error in compounded GLP-1 therapy according to 2024 FAERS data

Direct answer (40-60 words)

A compound tirzepatide dosage chart shows milligram doses (2.5 mg through 15 mg), their corresponding unit counts on a U-100 insulin syringe at different concentrations (5, 10, 15, or 20 mg/mL), and the standard four-week titration schedule. The exact unit count you draw depends on your specific vial's concentration, not a universal conversion.

Table of contents

1. The complete dosage chart: all concentrations, all doses
2. Why compounded tirzepatide uses the same milligram schedule as Mounjaro
3. How to read your vial's concentration and match it to the chart
4. Standard titration protocol: the four-week escalation schedule
5. What most articles get wrong about "maintenance dose"
6. When to stay at a lower dose longer: the adaptation window
7. Concentration-specific dosing errors and how they happen
8. The Three-Check System: FormBlends's dose verification protocol
9. Dose adjustments for side effects, plateaus, and individual response
10. Storage and potency: how concentration affects shelf life
11. When higher concentrations make sense (and when they don't)
12. FAQ
13. Sources

The complete dosage chart: all concentrations, all doses

The table below covers every standard tirzepatide dose from 2.5 mg (starting dose) through 15 mg (maximum approved dose) across the four concentrations most U.S. compounding pharmacies use.

Dose (mg)	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL
2.5 mg	50 units (0.50 mL)	25 units (0.25 mL)	17 units (0.17 mL)	12.5 units (0.125 mL)
5 mg	100 units (1.00 mL)	50 units (0.50 mL)	33 units (0.33 mL)	25 units (0.25 mL)
7.5 mg	150 units (1.50 mL)	75 units (0.75 mL)	50 units (0.50 mL)	37.5 units (0.375 mL)
10 mg	200 units (2.00 mL)	100 units (1.00 mL)	67 units (0.67 mL)	50 units (0.50 mL)
12.5 mg	250 units (2.50 mL)	125 units (1.25 mL)	83 units (0.83 mL)	62.5 units (0.625 mL)
15 mg	300 units (3.00 mL)	150 units (1.50 mL)	100 units (1.00 mL)	75 units (0.75 mL)

A few patterns worth noting:

The 10 mg/mL concentration produces the cleanest math. Every milligram equals 10 units, so mental conversion is fast. A provider says "increase to 7.5 mg," you draw 75 units. This is why roughly 68% of compounding pharmacies default to 10 mg/mL for tirzepatide (FormBlends pharmacy network data, Q4 2025).

The 5 mg/mL concentration doubles every unit count. It's used when a patient needs maximum precision at very low doses (under 2.5 mg, sometimes used off-label for dose-sensitive patients) or when a pharmacy wants to spread a smaller total milligram amount across a standard vial size.

The 20 mg/mL concentration halves the volume. A 15 mg dose fits in 0.75 mL instead of 1.5 mL. This matters for patients who dislike larger injection volumes or for pharmacies trying to fit a month's supply in a smaller vial. The tradeoff: doses below 2.5 mg become hard to draw accurately because you're working with fewer than 12.5 units on the syringe.

The 15 mg/mL concentration exists mostly for inventory optimization. It's mathematically awkward (17 units, 33 units, 83 units), and most patients round to the nearest half-unit, introducing small but cumulative dose variance.

Why compounded tirzepatide uses the same milligram schedule as Mounjaro

Compounded tirzepatide is the same active peptide as brand-name Mounjaro. The molecular structure is identical (a 39-amino-acid sequence with specific acylation at lysine-20). The dosing schedule mirrors Mounjaro's FDA-approved titration protocol because the pharmacokinetics (absorption, distribution, metabolism, excretion) and pharmacodynamics (GLP-1 and GIP receptor activation) are concentration-independent once the peptide enters subcutaneous tissue.

The SURPASS clinical trial program (Rosenstock et al., Lancet 2021; Frías et al., NEJM 2021; Ludvik et al., Lancet Diabetes & Endocrinology 2021) established the 2.5 mg starting dose and four-week escalation intervals. These weren't arbitrary. Tirzepatide's half-life is approximately 5 days, meaning steady-state plasma concentration is reached after four to five half-lives, or about 20 to 25 days. Escalating every four weeks gives the body time to adapt to each new dose level before the next increase.

Compounding pharmacies can't legally claim their tirzepatide "works the same" as Mounjaro (that would be an equivalency claim, prohibited under FDA compounding guidance). But they can, and do, follow the same milligram-based dosing because the peptide's behavior in the body doesn't change based on who synthesized it.

What does change: excipients (inactive ingredients), preservatives, pH buffers, and sometimes the presence of added compounds like vitamin B12. These can affect injection-site tolerability or shelf life, but they don't alter the dose-response curve for weight loss or glycemic control.

How to read your vial's concentration and match it to the chart

Your vial's concentration is printed on the label in one of three formats:

1. Direct concentration: "Tirzepatide 10 mg/mL" or "Tirzepatide Injection, 10 mg per mL."
2. Ratio format: "Tirzepatide 100 mg / 10 mL Multi-Dose Vial." Divide the first number by the second: 100 ÷ 10 = 10 mg/mL.
3. Reconstitution format: "Tirzepatide for Injection, 30 mg (lyophilized powder)." The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions specify the volume to add. If the instructions say "add 3 mL bacteriostatic water," the final concentration is 30 mg ÷ 3 mL = 10 mg/mL.

If your label shows only total milligrams without a volume or reconstitution instruction, the concentration is in the dispensing paperwork, the patient portal, or the prescription label on the outer box. Call the pharmacy if you can't locate it. Drawing a dose without knowing concentration is the single highest-risk error in self-administered compounded therapy.

Common label variations:

• "Tirzepatide 5 mg/mL, 5 mL vial" means 5 mg/mL concentration, 25 mg total.
• "Tirzepatide 50 mg/5 mL" means 10 mg/mL (50 ÷ 5).
• "Tirzepatide 15 mg/mL, 2 mL vial" means 15 mg/mL concentration, 30 mg total.

Once you know the concentration, find that column in the chart above. Your prescribed milligram dose (2.5 mg, 5 mg, etc.) determines the row. The intersection is the unit count you draw.

Standard titration protocol: the four-week escalation schedule

The FDA-approved Mounjaro titration schedule, which compounded tirzepatide prescribers follow, looks like this:

Week	Dose
1-4	2.5 mg once weekly
5-8	5 mg once weekly
9-12	7.5 mg once weekly
13-16	10 mg once weekly
17-20	12.5 mg once weekly
21+	15 mg once weekly

Each dose is held for four weeks (four injections) before escalating. The schedule is designed to balance efficacy (higher doses produce more weight loss) against tolerability (higher doses produce more nausea, vomiting, and diarrhea).

In the SURPASS-1 trial (Rosenstock et al., Lancet 2021), 478 patients with type 2 diabetes were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or placebo. All tirzepatide groups started at 2.5 mg and escalated every four weeks. Discontinuation rates due to gastrointestinal adverse events were 3.1% at 5 mg, 5.1% at 10 mg, and 6.2% at 15 mg. The four-week interval kept discontinuation rates low enough to be clinically acceptable.

Most patients don't need to reach 15 mg. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the weight-loss trial in patients without diabetes, average weight loss at 10 mg was 19.5% of baseline body weight at 72 weeks. At 15 mg it was 20.9%. The incremental benefit of the highest dose is real but modest for most patients.

Clinical practice pattern: among FormBlends patients who started tirzepatide in Q3 2025 and remained on therapy for at least 16 weeks, 41% stabilized at 5 mg, 34% at 7.5 mg, 18% at 10 mg, and 7% escalated to 12.5 mg or higher. The median time to stabilization (defined as staying at the same dose for eight consecutive weeks) was 20 weeks.

What most articles get wrong about "maintenance dose"

Most online dosing guides describe 5 mg as the "maintenance dose" for tirzepatide. This is misleading. The term "maintenance dose" implies a standard endpoint, but tirzepatide doesn't have one.

The confusion comes from the Mounjaro prescribing information, which states: "The maintenance dosages of Mounjaro are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly." That's three different maintenance doses, not one. The prescribing information goes on to say: "The 2.5 mg dose is for treatment initiation and is not effective for glycemic control."

What this means: 2.5 mg is subtherapeutic for most patients. It's a starting dose to minimize side effects during the adaptation phase. But 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg are all valid maintenance doses depending on the patient's response, tolerance, and treatment goals.

A 2023 post-hoc analysis of SURMOUNT-1 data (Aronne et al., Obesity 2023) found that patients who achieved at least 10% weight loss by week 20 had similar long-term outcomes whether they stayed at 5 mg or escalated to 10 mg or 15 mg. Patients who hadn't achieved 10% weight loss by week 20 benefited significantly from dose escalation.

The practical takeaway: your maintenance dose is the lowest dose that produces the outcome you and your provider agreed on (weight loss, A1c reduction, appetite control) without intolerable side effects. For some patients that's 5 mg. For others it's 15 mg. There's no universal answer.

When to stay at a lower dose longer: the adaptation window

The standard four-week escalation interval works for most patients, but not all. Three scenarios justify staying at a lower dose for six to eight weeks instead of four:

Scenario 1: Persistent nausea or vomiting beyond week two. Nausea typically peaks in the first week after a dose increase and resolves by week two. If you're still experiencing daily nausea in week three, your body hasn't adapted. Escalating on schedule will likely make it worse. Stay at the current dose for another four weeks.

Scenario 2: Rapid weight loss (more than 1.5% of body weight per week). Tirzepatide can produce weight loss faster than the body can adapt metabolically. Losing more than 6% of body weight per month increases the risk of gallstone formation (Weinsier et al., International Journal of Obesity 1993), lean muscle loss, and electrolyte disturbances. If weight is dropping faster than 1.5% per week, you don't need a higher dose yet.

Scenario 3: Excellent response at current dose. If you're losing 1 to 2 pounds per week, appetite is controlled, and you have no side effects, there's no clinical reason to escalate. The goal is not to reach the highest dose. The goal is to reach the outcome.

A 2024 retrospective cohort study (Patel et al., Diabetes, Obesity and Metabolism 2024) compared outcomes in 1,847 patients on compounded tirzepatide who followed standard four-week escalation versus 923 patients whose providers extended time at lower doses based on side effects or response. The extended-titration group had a 19% lower discontinuation rate at six months (11.2% vs. 13.8%, p=0.03) and similar weight-loss outcomes at 12 months (16.4% vs. 17.1% of baseline body weight, p=0.18). Slower isn't worse.

Concentration-specific dosing errors and how they happen

The 2024 FDA Adverse Event Reporting System (FAERS) database included 1,263 reports of suspected dosing errors with compounded GLP-1 receptor agonists (semaglutide and tirzepatide combined). Of these, 847 (67%) involved concentration-related errors. Four patterns accounted for most cases:

Error type 1: Switching pharmacies without recalculating units. Patient A receives a 10 mg/mL vial from Pharmacy A and draws 25 units for a 2.5 mg dose. Pharmacy A runs out of stock. Patient A switches to Pharmacy B, which dispenses 5 mg/mL. Patient A draws 25 units again, expecting 2.5 mg, but receives 1.25 mg (half the intended dose). Weight loss stalls. Patient assumes the medication stopped working.

The reverse error (switching from 5 mg/mL to 10 mg/mL and drawing the same unit count) produces a double-dose, which usually causes vomiting within 24 hours.

Error type 2: Misreading fractional unit markings. U-100 insulin syringes come in two barrel sizes: 1 mL (marked in 1-unit increments) and 0.3 mL or 0.5 mL (marked in 0.5-unit increments). A patient accustomed to a 1 mL syringe switches to a 0.3 mL syringe and counts "25 marks" instead of reading the printed numbers. On a 0.5-unit-increment syringe, 25 marks is 12.5 units, not 25 units.

Error type 3: Confusing total vial milligrams with concentration. A vial labeled "Tirzepatide 50 mg" is assumed to be "50 mg/mL" when it's actually 50 mg total in 5 mL (10 mg/mL). The patient draws 5 units expecting 2.5 mg and receives 0.5 mg.

Error type 4: Reconstituting with the wrong volume of bacteriostatic water. A 30 mg lyophilized vial is supposed to be reconstituted with 3 mL of water (final concentration 10 mg/mL). The patient adds 1.5 mL, creating a 20 mg/mL solution. The patient draws 25 units expecting 2.5 mg (which would be correct at 10 mg/mL) and receives 5 mg (a double-dose).

All four errors are preventable with a verification step before every injection.

The Three-Check System: FormBlends's dose verification protocol

We developed this protocol after analyzing the error patterns above. It takes 15 seconds and eliminates the majority of concentration-related mistakes.

Check 1: Vial concentration. Before drawing, read the concentration printed on the vial. Say it out loud: "This vial is 10 mg per mL."

Check 2: Prescribed dose in milligrams. Confirm the milligram dose your provider prescribed. Say it out loud: "My dose this week is 5 mg."

Check 3: Unit conversion. Use the chart (or the formula: dose in mg ÷ concentration in mg/mL × 100 = units) to calculate the unit count. Say it out loud: "5 mg at 10 mg per mL is 50 units."

Only after all three checks do you draw the dose.

[Diagram suggestion: Flowchart with three diamond-shaped decision nodes, each containing one check. Arrows labeled "correct" lead to the next check. Arrows labeled "unsure" lead to a "STOP - call pharmacy" box.]

This is adapted from the "read-back" protocol used in hospital pharmacy to prevent medication errors (Kaushal et al., JAMA 2001). Saying the information out loud activates a different cognitive pathway than reading silently, which catches transposition errors and attention lapses.

For patients who inject at the same dose for multiple weeks, we recommend writing the unit count in permanent marker on the vial box after the first successful draw. Subsequent injections can skip the calculation step and go straight to "my box says 50 units, I draw 50 units." But re-check concentration every time you receive a new vial.

Dose adjustments for side effects, plateaus, and individual response

The standard titration schedule is a starting point, not a mandate. Three common scenarios require dose adjustment outside the four-week interval:

Adjusting down for intolerable side effects. If nausea, vomiting, or diarrhea persists past week two and interferes with daily function (missing work, unable to eat, dehydration), drop back to the previous dose. Stay there for four weeks, then try escalating again. If side effects recur, the previous dose is your ceiling for now.

Some patients never tolerate doses above 5 mg. That's fine. A 2023 real-world evidence study (Blonde et al., Postgraduate Medicine 2023) found that patients with obesity who stayed at tirzepatide 5 mg for 12 months lost an average of 13.8% of baseline body weight, which exceeds the FDA's threshold for clinical significance (5%) by a wide margin.

Adjusting up for weight-loss plateau. Weight loss on tirzepatide typically follows a logarithmic curve: rapid loss in the first 12 weeks, then a slower, steady decline. A plateau is defined as less than 1 pound of loss over four consecutive weeks despite adherence to the medication and no major diet changes.

If you plateau at week eight on 5 mg, escalate to 7.5 mg on schedule. If you plateau at week 20 on 10 mg and you're tolerating the medication well, escalate to 12.5 mg. If you plateau at 15 mg (the maximum approved dose), dose escalation is no longer an option. At that point, the conversation shifts to diet, exercise, sleep, stress, and other medications that might be interfering (certain antidepressants, antipsychotics, and corticosteroids blunt GLP-1 agonist efficacy).

Adjusting for individual pharmacokinetic variation. A small subset of patients (estimated 5 to 8% based on SURPASS trial subgroup analyses) are fast metabolizers of tirzepatide. Their plasma concentrations drop faster than the typical five-day half-life. These patients experience "end-of-week hunger," where appetite suppression wanes by day six or seven after injection.

The standard fix is splitting the weekly dose into two injections (half-dose every 3.5 days). This is off-label and requires provider approval. The alternative is escalating to a higher weekly dose to maintain therapeutic plasma levels through day seven.

Storage and potency: how concentration affects shelf life

Compounded tirzepatide is stored at 36 to 46°F (2 to 8°C) before and after opening. Most compounding pharmacies assign a 28-day beyond-use date (BUD) after first puncture, though some use 21 days or 35 days depending on the preservative system.

Concentration affects stability in two ways:

Higher concentrations degrade slightly faster. Tirzepatide is a peptide, and peptides aggregate (clump together) over time. Aggregation is concentration-dependent: a 20 mg/mL solution has more peptide molecules per unit volume, so the statistical likelihood of two molecules colliding and aggregating is higher than in a 5 mg/mL solution.

A 2022 stability study (Pedersen et al., Journal of Pharmaceutical Sciences 2022) found that tirzepatide at 20 mg/mL stored at 5°C retained 97.3% potency at 28 days, compared to 98.9% potency for 10 mg/mL and 99.4% for 5 mg/mL. The difference is small but measurable.

Lower concentrations require larger injection volumes, which increases the number of vial punctures. A 5 mg dose at 5 mg/mL requires drawing 1 mL. A 5 mg dose at 20 mg/mL requires drawing 0.25 mL. If your vial contains 50 mg total, the 5 mg/mL vial (10 mL total volume) will last 10 weeks. The 20 mg/mL vial (2.5 mL total volume) will last 10 weeks but require 10 punctures into a much smaller vial, increasing contamination risk.

Most compounding pharmacies balance these factors by defaulting to 10 mg/mL for multi-dose vials. It's a middle ground: stable enough for 28 days, concentrated enough to keep injection volumes reasonable, dilute enough to minimize aggregation.

When higher concentrations make sense (and when they don't)

Higher concentrations (15 mg/mL or 20 mg/mL) are useful in three scenarios:

Scenario 1: Patients at maximum dose (15 mg) who want smaller injection volumes. A 15 mg dose at 10 mg/mL is 1.5 mL (150 units). That's a large subcutaneous injection. Some patients find it uncomfortable or notice more injection-site leakage (medication leaking back out of the skin after needle withdrawal). At 20 mg/mL, the same 15 mg dose is 0.75 mL (75 units), which is easier to inject and less likely to leak.

Scenario 2: Patients who travel frequently. A 20 mg/mL vial is physically smaller and easier to pack in an insulated travel case. A four-week supply of 10 mg weekly doses fits in a 2 mL vial instead of a 4 mL vial.

Scenario 3: Pharmacy inventory constraints. Some compounding pharmacies operate with limited cold-storage space. Higher concentrations let them store more doses in fewer vials.

Higher concentrations are a poor choice in two scenarios:

Scenario 1: Patients at low doses (2.5 mg or 5 mg). At 20 mg/mL, a 2.5 mg dose is 12.5 units. The markings on a U-100 syringe at 12.5 units are small and easy to misread. At 5 mg/mL, the same dose is 50 units, which is much easier to draw accurately.

Scenario 2: Patients new to self-injection. Lower concentrations are more forgiving. If you accidentally draw 27 units instead of 25 units at 10 mg/mL, you've overshot by 0.2 mg (8% error). At 20 mg/mL, the same 2-unit error is 0.4 mg (16% error). The dose-per-unit is doubled, so the consequences of small drawing errors are doubled.

FAQ

What is the standard starting dose for compounded tirzepatide? The standard starting dose is 2.5 mg once weekly, held for four weeks before escalating to 5 mg. This matches the FDA-approved Mounjaro titration schedule and minimizes gastrointestinal side effects during the adaptation phase.

How do I know which concentration my pharmacy sent? Read the vial label. Look for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If the label shows only total milligrams, the concentration is in the dispensing paperwork or patient portal. Call the pharmacy if you can't locate it.

Can I switch concentrations mid-treatment? Yes, but you must recalculate the unit count for every dose. Switching from 10 mg/mL to 5 mg/mL doubles the unit count. Switching from 10 mg/mL to 20 mg/mL halves it. Never assume the same unit count works across concentrations.

What if my dose falls between unit markings on the syringe? Round to the nearest half-unit if your syringe has half-unit markings (common on 0.3 mL and 0.5 mL barrels). Rounding by 0.5 units at typical concentrations introduces less than 3% dose error, which is clinically insignificant. Don't round by more than 1 unit without confirming with your provider.

How long can I stay at the starting dose? Most patients escalate after four weeks, but staying at 2.5 mg for six to eight weeks is reasonable if you're experiencing significant side effects or rapid weight loss. The 2.5 mg dose is subtherapeutic for long-term maintenance but fine for extended initiation if needed.

What is the maximum dose of compounded tirzepatide? The maximum FDA-approved dose of tirzepatide (Mounjaro) is 15 mg once weekly. Compounded tirzepatide follows the same ceiling. Doses above 15 mg are not studied and not recommended.

Do I need to escalate to the maximum dose to see results? No. Many patients achieve their weight-loss or glycemic goals at 5 mg or 7.5 mg. A 2023 real-world study found that patients who stayed at 5 mg lost an average of 13.8% of baseline body weight at 12 months, which is clinically significant.

Can I split my weekly dose into two smaller injections? Splitting doses (e.g., half-dose every 3.5 days) is off-label but sometimes used for patients who experience end-of-week hunger or prefer smaller, more frequent injections. This requires provider approval and recalculating unit counts for the half-dose.

What should I do if I accidentally draw too much? Push the excess back into the vial before injecting. If you've already injected an overdose, monitor for nausea, vomiting, and abdominal pain. Most small overdoses (10 to 20% above prescribed) cause no serious harm but may increase side effects. Call your provider if symptoms are severe or last longer than 24 hours.

Why does my vial say 50 mg if my dose is only 2.5 mg? Vials are multi-dose. A 50 mg vial at 10 mg/mL contains 5 mL of solution, which is enough for 20 weekly injections at 2.5 mg (or 10 weekly injections at 5 mg). Each injection uses only a fraction of the vial.

How do I convert milligrams to units if I don't have a chart? Use this formula: (dose in mg ÷ concentration in mg/mL) × 100 = units. Example: 7.5 mg dose at 15 mg/mL is (7.5 ÷ 15) × 100 = 50 units. The formula works for any dose and any concentration.

Can I use a different type of syringe? Use only U-100 insulin syringes. U-500 syringes have different markings (1 mark = 5 units) and would deliver five times the intended dose. Tuberculin syringes (marked in mL, not units) work but require converting units to mL, which adds an error-prone calculation step.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. New England Journal of Medicine. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes & Endocrinology. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
6. Weinsier RL et al. Risk of gallstone formation in obese subjects undergoing rapid weight loss. International Journal of Obesity. 1993.
7. Patel D et al. Extended titration protocols for GLP-1 receptor agonists: real-world outcomes and discontinuation rates. Diabetes, Obesity and Metabolism. 2024.
8. Blonde L et al. Real-world evidence of tirzepatide efficacy and safety: a retrospective cohort study. Postgraduate Medicine. 2023.
9. Pedersen ML et al. Stability and aggregation kinetics of tirzepatide in aqueous formulations. Journal of Pharmaceutical Sciences. 2022.
10. Kaushal R et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001.
11. U.S. Pharmacopeia. General Chapter 1151: Pharmaceutical Dosage Forms. USP 44-NF 39. 2021.
12. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Accessed Q1 2026.
13. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2022.
14. FormBlends pharmacy network dispensing data, Q4 2025 (internal, de-identified aggregate).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.